Eisai Co., Ltd. (ESAIY) 주가 예측

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. The company is headquartered in Bunkyo-Ku, Tokyo-To and currently employs 13,506 full-time employees. The firm operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The firm is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.